Research Papers:
MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2878 views | HTML 3134 views | ?
Abstract
Jing-Jun Yan1,2, Yu-Nan Zhang1, Jia-Zhi Liao1, Kun-peng Ke3, Ying Chang1, Pei-Yuan Li1, Min Wang2, Ju-Sheng Lin1, Xing-Xing He1
1Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
3Department of Cardiac Surgery, Wuhan Asia Heart Hospital, Wuhan 430022, China
Correspondence to:
Xing-Xing He, e-mail: [email protected]
Keywords: hepatocellular carcinoma, microRNA, tumor biology, cancer
Received: April 01, 2015 Accepted: August 10, 2015 Published: August 21, 2015
ABSTRACT
Hepatocellular carcinoma (HCC) is a worldwide malignance and displays marked vascular abnormalities and active metastasis. MicroRNAs (miRNAs) have been shown to play important roles in regulating tumor properties in cancer, however, whether miR-497 contributes to HCC angiogenesis or metastasis remains unclear. In this study, we found that miR-497 was significantly down-regulated in HCC tissue samples and cell lines. Gain-of-function and loss-of-function studies revealed that miR-497 could repress both the pro-angiogenic and metastatic ability of HCC cells. Subsequent investigations disclosed that miR-497 directly inhibited the 3′-untranslated regions (UTRs) of vascular endothelial growth factor A (VEGFA) and astrocyte elevated gene-1 (AEG-1). Furthermore, overexpression of these targets antagonized the function of miR-497. Based on nude mouse models, we demonstrated that overexpression of miR-497 significantly repressed microvessel densities in xenograft tumors and reduced pulmonary metastasis. In conclusion, our findings indicate that miR-497 downregulation contributes to angiogenesis and metastasis in HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5012